close

Sign up for a demo!

Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.
World Health Organization

Taking medicine as prescribed
is harder than you think

Life happens, and there are many both intentional and unintentional reasons for not taking your medicine, here are some of them.

Clinical trials

High statistical power with a smaller patient sample size

Real-time adherence data enabling support and follow up

Increased consistency and traceability through digitalization

Patient support

Material to support discussions and engagement with participants

Increased engagement, customer loyalty and patient insights

Remote interaction and adjustments
of treatment schedules

Healthcare

Guidance and support to take
or give the right dose at the right time

Material to discuss and present
adherence to caretaker or doctor

Registration of when a dose is
taken with no need of manual logging
Simply forgetting
Life gets in the way

Changing habits
Being unsure about getting the right treatment
Fear of side-effects

Remembering if you actually took it

Statistics

Clinical trials

Around 40% of participants enrolled in clinical studies do not take their medicine as prescribe after the first 150 days. This leads to longer more costly trials and an increased number of participants required to keep statistical power. As shown in the table, a one percent improvement of adherence can result in large cost savings in all trial phases. Being informed about the participants adherence also results in a faster dose strength selection. The dosing regime selection is a leading reason for delays in regulatory approval of a drug.
References: M.Alsumidaie (2017) Non-Adherence: A Direct Influence on Clinical Trial Duration and Cost
Average cost savings with 1% improved adherence
in clinical trials (US dollar)
Today’s cost of non-adherence

Medical treatment

Poor adherence leads to a decreased number of days on treatment, unnecessary treatment switches and large financial losses. On a global scale, non-adherence is estimated to reach an avoidable cost of 171 billion US dollars per year for the healthcare system.
References: T.Aitken et al. (2012) Advancing the Responsible Use of Medicines: Applying Levers for Change

Clinical trials

Around 40% of participants enrolled in clinical studies do not take their medicine as prescribe after the first 150 days. This leads to longer more costly trials and an increased number of participants required to keep statistical power. As shown in the table, a one percent improvement of adherence can result in large cost savings in all trial phases. Being informed about the participants adherence also results in a faster dose strength selection. The dosing regime selection is a leading reason for delays in regulatory approval of a drug.
Average cost savings with 1% improved adherence in clinical trials (US dollar)
References: M.Alsumidaie (2017) Non-Adherence: A Direct Influence on Clinical Trial Duration and Cost

Medical treatment

Poor adherence leads to a decreased number of days on treatment, unnecessary treatment switches and large financial losses. On a global scale, non-adherence is estimated to reach an avoidable cost of 171 billion US dollars per year for the healthcare system.
Today’s cost of non-adherence


Without any objective measurement of drug compliance, physicians have become used to opting almost always...for enhancing doses or prescribing new drug combinations...However, there is usually no rational basis for this decision
As Burnier et al.

Patient health

Not taking medication as prescribed leads to poor health outcomes. Only in the United States, non-adherence is associated with 125 000 deaths, 10% of hospitalisations and $100 billion in health care services annually. Globally, non-adherence is estimated to cause 33% to 69% of medication-related hospital admission.
References: V.Kini and P.M Ho (2018) Interventions to Improve Medication Adherence: A review, L.Osterberg and T.Blaschke (2005) Adherence to Medication
33%-69%
Of medication-related hospital admission
caused by non-adherence
Among patients with chronic illnesses
do not take medications as prescribed

Chronic diseases

Treatment of chronic illnesses commonly includes long-term medication. Although these medications are effective, their full benefits are often not realised because approximately 50% of patients do not take their medicine as prescribed. This leads to increased illness and death and is estimated to result in costs of $100 billion per year.
References: M.T Brown and J.K Bussell (2011) Medication Adherence: WHO Cares?  

Patient health

Not taking medication as prescribed leads to poor health outcomes. Only in the United States, non-adherence is associated with 125 000 deaths, 10% of hospitalizations and $100 billion in health care services annually. Globally, non-adherence is estimated to cause 33% to 69% of medication-related hospital admission.
References: V.Kini and P.M Ho (2018 )Interventions to Improve Medication Adherence: A review, L.Osterberg and T.Blaschke (2005) Adherence to Medication
33%-69%
Among patients with chronic illnesses do not take medications as prescribed

Medical treatment

Poor adherence leads to a decreased number of days on treatment, unnecessary treatment switches and large financial losses. On a global scale, non-adherence is estimated to reach an avoidable cost of 171 billion US dollars per year for the healthcare system.
References: T.Aitken et al. (2012) Advancing the Responsible Use of Medicines: Applying Levers for Change
Among patients with chronic illnesses do not take medications as prescribed

Testing Mevia’s solutions

Case studies

Case study 1:
In a home care setting, Mevia's solutions were used on 21 residents between the ages of 75 and 90. During the 3-month study, medical deviation decreased from 60% to 14% compared to the same period the year before.
Case study 2:
Fifteen subjects over 80 years of age used Mevia's solutions with placebo medication in multi-dose packages for 4 weeks. With the support of the application, the adherence was 87%.
Download study
Adherence deviation
without Mevia’s solution
Adherence deviation
with Mevia’s solution
Accuracy that the pill actually is taken when it has been taken out from the package.

Is the dose really taken?

Our solutions use electronic monitoring to measure when a pill is taken out from the package. When taken out from the package, studies confirm that 97% also consumes the pill.
Reference: M.Burnier (2019) Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug Adherence

Case studies

Case study 1:
In a home care setting, Mevia’s solutions were used on 21 residents with over 40 people from home care personnel involved. The residents were distributed as 48% male and 52% female with ages ranging between 75-90. During the 3-month study, medical deviation decreased from 60 % to 14 % compared to the same period the year before.
Case study 2:
Fifteen subjects over 80 years of age used Mevia’s solutions with placebo medication in multi-dose packages for 4 weeks. This group of elderly had beforehand been trained in using a smart phone or tablet. The communication and reminders were sent to them via the app. With the support of the service the adherence was 87 %.
Download study report
Adherence deviation
without Mevia’s solution
Adherence deviation
with Mevia’s solution

Is the dose really taken?

Our packaging solutions use electronic monitoring to measure when a pill is taken out from the package. Conceptually, this is an indirect measure of adherence and one cannot assure that once a pill is taken out of the package, the pill is taken. However, studies have confronted this and found a 97% accuracy between the time when a pill is taken out from the package and when it is actually being consumed.
Reference: M.Burnier (2019) Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug Adherence
Adherence deviation without Mevia’s solution

Failure to confirm efficacy,
example: HIV therapy

When self-reporting, 90% reported that they adhere to treatment. When pill-counting it turns out 86% of the patients were adhering to treatment, not 90%. When taking plasma samples through blood tests it turned out only 30% were adhering to treatment, a far less percentage than what was reported by the patients themselves and through pill-counting.
References: Marrazzo JM; VOICE Study Team. “Tenofovir-based preexposure prophylaxis for HIV infection among African women”. N Engl J Med. Article. 2015. Nov. 2020.
Adherence based on self-reports
Adherence based on returned-products counts
Adherence based plasma samples through blood tests

Interested in our solutions?

This website use cookies